Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $46.2M | $34.1M | $29M | -$188K | $5.9M | |
| Gross Profit | $31.5M | $21.9M | $18.8M | -$2.9M | $3.5M | |
| Operating Income | $26.1M | $16.8M | $20M | $5.9M | -$13K | |
| EBITDA | $26.6M | $16.9M | $20M | $5.9M | -$13K | |
| Diluted EPS | $0.45 | -$0.09 | $0.24 | $0.13 | -$0.40 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.2M | $18.4M | $17.7M | $22.5M | $7.2M | |
| Total Assets | $537.2M | $538.2M | $477M | $418.5M | $378.2M | |
| Current Liabilities | $32.7M | $6.1M | $6.1M | $19.4M | $36M | |
| Total Liabilities | $347.2M | $356.2M | $306.3M | $267.2M | $241.8M | |
| Total Equity | $190M | $182.1M | $170.7M | $151.3M | $136.3M | |
| Total Debt | $314M | $349.7M | $300.1M | $247.2M | $236.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $19.1M | $34.4M | $1.2M | $17.3M | $1.2M | |
| Cash From Investing | $52M | $42.1M | $14.2M | $2M | $4.8M | |
| Cash From Financing | -$68.3M | -$72.1M | -$30.6M | -$4.6M | -$11.3M | |
| Free Cash Flow | $19.1M | $34.4M | $1.2M | $17.3M | $1.2M | |
OFS Capital Corp. is a business development company, which invests in middle market companies located in the United States. It provides financing for recapitalizations and refinancing, MBOs, LBOs, acquisition financing, shareholder liquidity events, growth capital investments, and ESOPs with an investment of million. The company was founded on March 20, 2001 and is headquartered in Chicago, IL.
In the current month, OFS has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The OFS average analyst price target in the past 3 months is $7.00.
According to analysts, the consensus estimate is that OFS Capital Corp. share price will rise to $7.00 per share over the next 12 months.
Analysts are divided on their view about OFS Capital Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that OFS Capital Corp. is a Sell and believe this share price will drop from its current level to $7.00.
The price target for OFS Capital Corp. over the next 1-year time period is forecast to be $7.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
According to Wall Street analysts, the consensus rating for OFS Capital Corp. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
You can purchase shares of OFS Capital Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase OFS Capital Corp. shares.
OFS Capital Corp. was last trading at $4.56 per share. This represents the most recent stock quote for OFS Capital Corp.. Yesterday, OFS Capital Corp. closed at $4.60 per share.
In order to purchase OFS Capital Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.